在PBC中的PPAR激动剂:我们从这里走到哪里? 还是如何在新旧之间做出选择
Atsushi Tanaka1, Christophe Corpechot2
1Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Clinics and research in hepatology and gastroenterology
|April 27, 2024
概括
新的过氧酶增殖器激活受体 (PPAR) 激动剂对初级胆道胆炎 (PBC) 有希望,但需要长期数据. 现实世界的数据表明,贝萨菲布拉特可能会提供类似的长期益处,这构成了治疗选择的挑战.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 初级胆道胆炎 (PBC) 是一种慢性肝病,需要长期治疗.
- 乌尔苏多氧胆酸 (UDCA) 是一种标准治疗方法,但许多患者的反应不完全.
- 过氧体增殖器激活受体 (PPAR) 激活剂正在作为PBC的新疗法进行研究.
研究的目的:
- 评估PPAR激动剂在PBC患者的短期和长期疗效.
- 为了比较新的选择性PPAR激动剂的结果与现有的选择,如贝扎菲布拉特.
- 探索现实世界数据 (RWD) 在评估长期治疗疗效方面的实用性.
主要方法:
- 对新型PPAR激动剂的第三阶段试验数据的分析.
- 关于贝扎纤维酸的有效性和安全性的真实世界数据 (RWD) 的审查.
- 在PBC管理中评估代用终点和长期结果.
主要成果:
- 第三阶段试验显示,对新的PPAR激动剂有希望的短期生化反应.
- 贝扎菲布拉特,非标签使用,证明了短期的益处,减少了,并改善了长期的结果.
- 现实数据支持PPAR激动剂的疗效,但需要长期验证,特别是对于组合疗法.
结论:
- 选择新的选择性PPAR激动剂和PBC治疗贝扎纤维酸之间的选择需要仔细考虑长期结果.
- 对新型PPAR激动剂的前景试验可能具有挑战性;RWD方法对于长期有效性验证至关重要.
- 识别不耐受或对PPAR激动剂不反应的患者对于优化PBC治疗至关重要.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
86
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
86
Direct-Acting Cholinergic Agonists: Therapeutic Uses
731
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
731
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
169
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
169
Acute Pancreatitis II: Clinical Manifestations and Management
122
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
122
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
950
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
950
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


